Trastuzumab Deruxtecan with Bevacizumab for HER2-Expressing Ovarian Cancer
Tests trastuzumab deruxtecan with bevacizumab in adults with HER2-expressing advanced ovarian cancer.
Plain-language title generated from the registry record
Registry title: Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Key facts
- Where
- Athens, Chaïdári, Pireas, and Thessaloniki, GreeceSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with newly diagnosed advanced high-grade epithelial ovarian cancer whose tumor shows HER2 expression. It tests trastuzumab deruxtecan with bevacizumab against bevacizumab alone as first maintenance treatment.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Newly diagnosed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, FIGO Stage III or IV
- Earlier treatment
- Newly diagnosed; the trial gives first-line maintenance treatment
- Biomarker or test result
- The tumor must show HER2 expression (IHC 3+/2+/1+)
Main reasons for not taking part
- Cancer that is not of epithelial origin
- Known or suspected harmful BRCA change that makes a person able to take a PARP inhibitor
- Planned PARP inhibitor as maintenance treatment
- Stroke, transient ischemic attack or brain-surface bleeding in the 6 months before randomization
- Bleeding disorder or significant clotting problem, or a history of bleeding disorders
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- Which best describes your most recent course of platinum chemotherapy (such as carboplatin or cisplatin)?
- Have your doctors told you that your cancer is advanced (stage 3 or 4)? This means it has spread beyond the ovaries to other parts of the belly or the body, even if it was later removed by surgery.
- What type of ovarian cancer do you have?
Source: NCT06819007, who can take part
Where in Greece
- Alexandra HospitalAthens, GreeceTaking people
- Areteio HospitalAthens, GreeceTaking people
- University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"Chaïdári, GreeceTaking people
- Metropolitan HospitalPireas, GreeceTaking people
- St. Luke's Hospital S.A.Thessaloniki, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT06819007EU 2024-516982-35-00
- Record updated
- 28 October 2026
- Original description
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.Read full original descriptionShow less
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Inclusion: Sign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the Main ICF prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures; *For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures; Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old; Has histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous); Is newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV; Has HER2 expression.
Exclusion: Has a known or suspected deleterious BRCA alteration as per local test that makes the participant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor; Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion; Previous cerebral-vascular accident, transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization; *Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable; Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin; Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation therapy); Has a history of hemorrhagic disorders.